These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...

Researchers identify protein that mimics exercise to boost bone strength in aging adults

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine at the University of ...
Targeted Oncology

A Paradigm Shift in Bladder Cancer: Dr Jacob on the FDA Approval of TAR-200

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates ...
Becker's Spine Review

New treatments, AI advancements top wins for orthopedic surgeons this year

The development of new orthobiologic treatments and the smooth integration of AI are top accomplishments for these two orthopedic surgeons. Michael Stone, MD, and Bob Yin, MD, recently connected with ...
BioWorld

Mereo and Ultragenyx stagger as phase IIIs in brittle bones fail

Two phase III studies of setrusumab, Orbit and Cosmic, for treating brittle bones have failed and left the developers floundering on Wall Street. Neither of Ultragenyx Pharmaceutical Inc. and Mereo ...